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The role of non-coding RNAs in determining growth, productivity and recombinant product 
quality attributes in Chinese hamster ovary (CHO) cells has received much attention in recent 
years, exemplified by studies into microRNAs in particular. However, other classes of non-
coding RNAs have received less attention. One such class are the non-coding RNAs known 
collectively as long non-coding RNAs (lncRNAs). We have undertaken the first landscape 
analysis of the lncRNA transcriptome in CHO using a mouse based microarray that also 
provided for the surveillance of the coding transcriptome. We report on those lncRNAs present 
in a model host CHO cell line under batch and fed-batch conditions on two different days and 
relate the expression of different lncRNAs to each other. We demonstrate that the mouse 
microarray was suitable for the detection and analysis of thousands of CHO lncRNAs and 
validated a number of these by qRT-PCR. We then further analysed the data to identify those 
lncRNAs whose expression changed the most between growth and stationary phases of 
culture or between batch and fed-batch culture to identify potential lncRNA targets for further 
functional studies with regard to their role in controlling growth of CHO cells. We discuss the 
implications for the publication of this rich dataset and how this may be used by the community.  
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Mammalian expression systems are widely used for the production of recombinant protein 
biopharmaceuticals, largely due to their ability to correctly fold, assemble, post-translationally 
modify and secrete complex human like proteins [1]. Among these, the Chinese hamster ovary 
(CHO) cell is the most widely utilised expression platform used in industry, especially for the 
production of monoclonal antibodies (mAbs), and are used for the expression of more than 
60% of biotherapeutic proteins made in mammalian cells [1±5]. The most widely used 
bioprocess for the production of biopharmaceuticals from CHO cells involves fed-batch 
culture, this offering an advantage over batch culture in terms of cell growth, viability and 
product yields due to the supplementation of nutrients resulting in higher biomass 
accumulation, less build-up of toxic metabolic by-products and enhanced productivity [6±8].  
The prominence of CHO cell expression systems has driven innovation in the industry such 
that CHO expression systems and associated bioprocesses have been developed that can 
deliver yields of mAb in excess of 5-10 g/L in stably expressing, fed-batch systems [9,10]. 
Despite this, some biotherapeutic recombinant proteins, and particularly some of the non-mAb 
novel biotherapeutics in development, remain difficult to express in CHO cell or other 
mammalian cell expression systems [11,12]. Using a prior knowledge about cellular systems, 
various approaches have been taken to engineer cells to deliver enhanced product yields and 
quality including the engineering of chaperones [13,14], glycosylation machinery [15±17] and 
proliferation control strategies, including manipulation of the cell cycle [18,19] , apoptosis 
[20,21] and autophagy [22,23]. A long side this approach, there have been studies to further 
our understanding of the potential cellular constraints on the production of mAbs [24,25], other 
recombinant biotherapeutics [26] and difficult to express recombinant proteins [27] in order to 
identify bottlenecks in the recombinant gene expression pathway and to develop new 
bioprocesses or adapt/engineer novel hosts for enhanced production and/or quality of such 
molecules [28,29]. The majority of these studies to date have focussed upon manipulation of 
coding genes, however with the discovery and improved understanding of non-coding RNA in 
the control of cellular processes, there has been much interest in the last decade or so in these 
non-coding RNAs in CHO cells. In particular, the manipulation of microRNAs to enhance the 
ability of CHO cells to produce biotherapeutic proteins has attracted much attention [30±33]. 
An advantage of manipulating such non-coding RNAs for modulating CHO cell phenotypes is 
that such engineering does not place an addition protein synthetic burden upon the host cell  
[34], unlike engineering of coding genes, and often such non-coding RNAs can modulate 
whole pathways rather than individual steps or processes as when manipulating many coding 
genes. 
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It has been estimated that at least 75% of transcripts originate from non-coding sequences 
[35]. Investigations into these transcripts has resulted in the identification of a class of 
transcript collectively known as Long non-coding RNAs (lncRNAs) [36]. LncRNAs are defined 
as transcripts longer than 200 nucleotides that lack a significant open reading frame (ORF), 
are XVXDOO\WUDQVFULEHGE\51$SRO\PHUDVH,,DQGVSOLFHGZLWKRUZLWKRXW¶polyadenylation 
[37±39]. A number of lncRNA molecules have been shown to play key regulatory roles in 
various biological processes including epigenetic regulation [40], transcriptional control [41], 
splicing events [42], and mRNA translation [43]. Indeed, lncRNAs are capable of modulating 
a wide range of cellular processes and mechanisms both in the nucleus and the cytoplasm 
[44]. The majority of our understanding into lncRNAs and the mechanism(s) by which they 
elicit their responses has come from studies relating to disease [45] and developmental 
studies [46]. LncRNAs elicit their effects by acting as competing endogenous RNAs (ceRNAs) 
by binding to and sequestering microRNAs [47], by acting as architectural RNAs (arcRNAs) 
whereby they form functional structures [48], act as cis molecules to enhance (eRNAs) coding 
gene expression [49] or as trans protein binding RNA molecules that can recruit chromatin 
modifying [50,51], as microRNA precursors [52], modulators of mRNA stability [53] and to 
impact upon post-translational modifications [54,55].  
Despite the importance of lncRNAs in controlling cellular processes, and unlike small non-
coding RNAs (e.g. siRNAs, microRNAs), the impact(s) of lncRNA expression on CHO cell 
bioprocessing with regard to growth/proliferation and recombinant protein yields and quality 
has barely been explored, with only a small number of studies reported [56,57]. However, 
these two studies show that manipulation of lncRNAs can impact upon recombinant protein 
production from CHO cells. One of the reasons for the small number of studies on lncRNAs in 
CHO cells is the lack of a comprehensive annotation of non-coding transcripts in CHO, 
hampering their identification, genome wide assessment of their expression and modulation 
during culture, functional studies and hence identification of target lncRNAs for cell 
engineering. One way to address this problem is to take advantage of the reported similarities 
between the Chinese hamster, CHO and mouse genome [58], where the number of well 
annotated non-coding transcripts is much higher. The similarity between CHO cells and mouse 
has already been utilised for the identification of 416 ncRNAs based on sequenced transcripts 
from a pooled CHO sample compared to the fRNAdb database of non-coding RNAs using 
BLAST, with most hits coming from mouse [59]. Here, we report the first analysis in CHO cells 
of both the coding and the non-coding transcriptome (specifically the lncRNAs) during batch 
and fed-batch culture at two different time points. We report on the identification of differentially 
expressed lncRNAs and mRNA, their interconnections and their potential impact on cellular 
pathways. This has allowed the mapping of the lncRNA landscape in CHO cells and 
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identification of lncRNAs targets in CHO for further manipulation with a view to increase 
proliferation and to sustain viability throughout batch and fed-batch culture.  
2. Materials and Methods 
2.1 Model Cell Line and Cell Culture Conditions 
The CHO-S Freestyle host cell line (ThermoFisher Scientific, MA, USA) was used as a model 
CHO cell line for this study. Cells were routinely cultured in a Lab-Therm LT-X (Kühner AG, 
Basel, Switzerland) shaking incubator at 37°C, 5% CO 2, 125 rpm and 70% humidity in 
chemically de¿ned serum-free growth medium (CD CHO, ThermoFisher Scientific, MA, USA). 
Fed-batch cultures were supplemented with CHO CD Efficient Feed B Liquid Nutrient 
Supplement (ThermoFisher Scientific, MA, USA). Initial supplementation testing was 
conducted in duplicate following Conditions 3 and 9 as described in the CHO CD Efficient 
Feed manual.  Cultures with a viability >98% were used to seed initial fed experiments at 
3x105 viable cells/mL in a 50 mL working volume in 250 mL polycarbonate Erlenmeyer flasks 
with vented caps (Corning, Wiesbaden, Germany). From the initial feeding experiments, 
Condition 3 was used for all future fed-batch cultures and for generating samples analysed 
during this study. This adopted feeding strategy consisted of a 15% (v/v) supplementation of 
CHO CD Efficient Feed B to the CD CHO starting volume immediately on Day 0, followed by 
10% (v/v) supplementation on Day 3 and Day 6. Four biological replicates of each culture 
process (batch and fed-batch) were seeded at 3x105 viable cells/mL from 20 mL cultures with 
a culture YLDELOLW\   LQ  P/ &' &+O starting working volume in 500 mL 
polycarbonate Erlenmeyer flasks with vented caps (Corning). Viable cell concentrations and 
culture viability were determined daily using a Vi-CELL XR Cell Viability Analyzer (Beckman 
Coulter, Inc., Brea, CA, USA) on 1 mL culture samples.  
2.2 Sampling from Cell Cultures and Subsequent RNA Extraction 
Samples of 1 x 107 viable cells were taken from each flask after 96 hours (day 4) and 144 
hours (day 7) of culture and total RNA immediately extracted using the commercially available 
mirVana miRNA Isolation Kit (ThermoFisher Scientific, MA, USA) and treated with RapidOut 
DNA Removal Kit (ThermoFisher Scientific, MA, USA). The RNA quantity and quality were 
determined using a NanoDrop ND-1000 (ThermoFisher Scientific) instrument and the integrity 
of RNA assessed by standard denaturing agarose gel electrophoresis. 
2.3 lncRNA and Coding RNA Microarray and Data Analysis  
2.3.1 Microarray Details 
Three of the 4 cultures were selected for analysis. Analysis of extracted RNA for coding and 
lncRNAs was undertaken using the commercially available ArrayStar Mouse lncRNA 
Microarray V3.0 (Rockville, MD, USA). RNA labelling and array hybridization were performed 
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according to the Agilent One-Color Microarray-Based Gene Expression Analysis protocol 
(Agilent Technologies, Santa Clara, CA, USA) with minor modifications. Ribosomal RNAs 
were removed from total RNA using the mRNA-ONLY Eukaryotic mRNA Isolation Kit, 
(Epicentre, Madison, WI, USA). Each sample was then amplified and transcribed into 
IOXRUHVFHQWF51$DORQJWKHHQWLUHOHQJWKRIWKHWUDQVFULSWVZLWKRXW¶ELDVXWLOL]LQJDPL[WXUHRI
oligo(dT) and random primers using the Arraystar Flash RNA Labelling Kit (Arraystar). The 
labelled cRNAs were purified by RNeasy Mini Kit (Qiagen, Hilden, Germany). The 
concentration and specific activity of the labelled cRNAs were determined by NanoDrop ND-
1000 (ThermoFisher Scientific). A total of 1 ȝg of each labelled cRNA was then fragmented 
by adding 5 ȝL of 10 × Blocking Agent and 1 ȝL of 25 × Fragmentation Buffer before heating 
at 60°C for 30 min. Finally, 25 ȝL of 2 × GE Hybridization buffer was added to dilute the labelled 
cRNA. A sample of 50 ȝL of the hybridization solution was then dispensed into the gasket 
slide and assembled to the LncRNA expression microarray slide. The slides were incubated 
for 17 hours at 65°C in a Microarray Hybridization Oven  (Agilent Technologies). The hybridized 
arrays were then washed, fixed and scanned using the G2505C DNA Microarray Scanner 
(Agilent Technologies).  
2.3.2 Microarray Data Analysis  
Agilent Feature Extraction software (version 11.0.1.1) was used to analyse acquired array 
images. Quantile normalization and subsequent data processing were performed using the 
GeneSpring GX v12.1 software package (Agilent Technologies). After quantile normalization 
of the raw data, lncRNAs and mRNAs that were present in t3 of 12 samples were selected 
for further data analysis. Raw p-values were calculated by unpaired t-test, then the 
differentially expressed lncRNAs and mRNAs with statistical significance between compared 
groups were filtered for a )&DQGDfalse discovery rate (FDR) 0.10 calculated by the 
Benjamini±Hochberg procedure. GO analysis was performed using the Bioconductor package 
topGO [60] and with a raw p-value cut-off of 0.05 FDOFXODWHG E\ )LVKHU¶V H[DFW WHVW, 
subsequently filtered for an FDR . Pathway analysis for differentially expressed mRNAs 
was performed based on the KEGG database (http://www.genome.jp/kegg) with a raw p-value 
cut-RIIRIFDOFXODWHGE\)LVKHU¶VH[DFWWHVWVXEVHTXHQWO\ILOWHUHGIRUDQ)'5. 
2.4 RT-qPCR Validation of lncRNAs Identified as Differentially Expressed by Microarray 
Primers for RT-qPCR were designed using OligoPerfect Designer (ThermoFisher Scientific) 
and synthetized by Eurofins Scientific (Luxembourg) (described in Supplementary Table 1). 
RT-qPCR reactions were conducted using a Mastercycler EP Realplex instrument 
(Eppendorf) following the QuantiFast SYBR Green RT-PCR Kit protocol (Qiagen). Specificity 
of amplification was checked by the generation of Tm curves and by analysis of the reaction 
products by 2% agarose gel electrophoresis to confirm the presence of a single amplicon of 
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the expected size. The results were analysed applying the standard ǻCt method and 
normalized to GAPDH, E-actin and B2M housekeeping gene expression.  
3. RESULTS 
3.1 Growth Characteristics and Sampling of CHO-S Cells Throughout Batch and Fed-
Batch Culture for (Non)-Coding RNA Analysis 
The steps followed to generate the results presented in this work are summarized in Fig. 1. 
Initially, growth comparisons and supplementation testing were undertaken using CD CHO 
and the associated commercially available feds (Efficient Feds A and B). From these 
preliminary experiments, we selected Efficient Feed B Liquid Nutrient Supplement for 
experimental Fed-batch cultures as this gave the highest viable cell concentrations across a 
10-day process from the feed strategies investigated (data not shown). Cells under Fed or 
Batch culture grew almost identically up until day 4 of culture whereupon their growth 
characteristics differed (Fig. 2A). Whilst growth of the Batch cultures slowed dramatically after 
day 4, with a mean peak viable cell concentration on day 6 of approximately 1 x 107 cells/mL, 
in the Fed-batch cultures growth and proliferation continued until day 6 where a mean peak 
viable cell concentration of almost 2 x 107 cells/mL was obtained (Fig. 2A). After day 6 the 
viable cell number and viability of both cultures decreased with time, however while culture 
viability rapidly declined in the Batch culture such that by day 9 culture viability was close to 
0%, in the Fed-batch mode cultures had a mean viability of 83.6% at day 10 (Fig. 2A). The 
first-time point at which samples were harvested was Day 4, when both types of culture had 
grown in a similar way and were still in the exponential growth phase (late exponential for 
batch), whilst the second time point at which cells were harvested for RNA analysis was on 
Day 7, corresponding to the end of the stationary phase/first day of decline for both cultures. 
In the case of the Fed-batch cultures, these two sampling points were also 24 hours after 
addition of the Efficient Feed B. 
3.2 Microarray Analysis of mRNA and lncRNA Transcripts in Batch and Fed-Batch 
Culture  
3.2.1 Differential expression of lncRNAs and mRNAs in Fed-batch v Batch comparisons 
The Arraystar Mouse LncRNA Microarray V3.0 used in this study is based on publicly available 
databases and publications, allowing for the potential simultaneous surveillance of 35923 
lncRNAs and 24881 coding transcripts. The lncRNAs collection is based on the NCBI Refseq, 
UCSC Known Gene 6.0, Ensembl 38.71, Fantom3, RNAdb 2.0, NRED databases, a number 
of literature publications, T-UCRs, and evolutionary constrained lncRNAs [61±68]. Positive 
probes for housekeeping genes and negative probes are printed onto the array for 
hybridization quality control. After quantile normalization of the raw data, 24603 unique 
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lncRNAs and 19617 mRNAs were selected for analysis. Firstly, we implemented Principal 
Component Analysis (PCA) on the log2 transformed intensities and plotted the first 3 
components against each other, where lncRNAs and mRNAs showed very comparable 
results, especially where for the first two components samples from Batch cultures at both 
days grouped closely compared to Fed-batch samples, which showed a wider separation even 
between the same condition (Supplementary Figure 1). Then we applied hierarchical 
clustering, arranging samples into groups based on their averaged log-normalized expression 
levels to show the relationships among gene expression patterns of samples for both lncRNAs 
and mRNAs (Fig. 2B). We continued performing differential expression analysis (DE) where 
we compared Fed-batch against Batch at Day 4, Fed-batch against Batch at Day 7, Fed-batch 
at Day 7 against Fed-batch at Day 4 and Batch at Day 7 against Batch at Day 4.  At this point, 
the expression of a selected number of the identified DE transcripts was confirmed by RT-
qPCR, that showed these transcripts were present but that lower fold-changes were observed 
between samples than from the array analysis (Supplementary Table 1). The genes identified 
as DE were then filtered based on a threshold IROGFKDQJH)&DQGDIDOVHGLVFRYHU\UDWH
)'5(Supplementary Tables 2 & 3). When we compared Batch Day 7 to Batch Day 
4 samples, we found surprisingly low numbers of mRNAs or lncRNAs where the expression 
changed beyond the set thresholds, with 0 mRNAs being up and 19 down regulated between 
the two days whilst for the lncRNAs there were no transcripts that changed about the 
thresholds set (Fig. 2C). To check whether this lack of identified transcripts changing was due 
WRWKH)&WKUHVKROGZHUHSHDWHGWKHDQDO\VLVIRU)&DQG)&)'5 0.10 
(Supplementary Tables 4-11).  )RUD)&   mRNAs were down and 30 were up-
regulated while none met the threshold for the lncRNAs.  We then carried on with the )&
)'5WKUHVKROGVIRU the remaining comparisons. Fed-batch Day 7 vs Day 4 revealed 
693 mRNAs up-regulated and 421 down-regulated whilst for the lncRNAs we found 545 up-
regulated and 200 down-regulated genes (Fig. 2C). When we compared Fed-batch against 
Batch at Day 4 and Day 7, 1048 and 1875 lncRNAs were up-regulated respectively in addition 
to 856 down-regulated at day 4 and 1018 down-regulated at day 7. For the same comparisons 
we saw more down-regulated mRNAs at day 4 (1538) and day 7 (1397) while there were 716 
up-regulated mRNAs at day 4 and 1121 at day 7 (Fig. 2C).  
3.3 Identification of lncRNAs Differentially Expressed as Potential Engineering Targets 
for Modulation of Cell Growth 
As one of the aims of this work was to identify new transcripts for manipulation in CHO, we 
reduced the list of potential targets to a manageable group for further experimental validation. 
Firstly, we aligned all the 60 nucleotide mouse probes corresponding to the differentially 
expressed genes identified for each comparison against the Chinese hamster (CH) genome 
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using the discontiguous megablast algorithm to check how many transcripts had an annotation 
in CHO. Only 16-28% of the probes corresponding to differentially expressed lncRNAs had a 
matching transcript in CH, as opposed to 58-80% of the mRNAs (Supplementary Table 12). 
This is likely due to the poor annotation of the CH transcriptome compared to mouse, where 
the number of described lncRNAs is significantly higher. If we consider the ENSEMBL 91 
database release alone, 2563 lncRNAs and 446 pseudogenes are listed for Chinese hamster 
as opposed to 9308 lncRNAs and 12363 pseudogenes in mouse. To address this issue we 
complemented this approach with literature and databases mining (NCBI, ENSEMBL, 
lncRNAdb, LNCipedia) to identify differentially expressed lncRNAs already described in 
mouse but not in Chinese hamster, revealing genomic positions that align with potential 
lncRNAs (Supplementary Figures 2-4). The identified sequences were then examined using 
the Rfam database [69] to assess their resemblance to existing non-coding RNA families. A 
list of potential lncRNAs found using the described approaches is reported in Table 1, along 
with literature references describing their biological function. 
The role of lncRNAs in diseases is well established, especially linked to cell proliferation in 
cancer [70] and several of those identified here have been investigated in such systems. 
NEAT1 (nuclear-enriched abundant transcript 1) and MALAT1 (also known as NEAT2), found 
to be up-regulated at both days in our Fed-batch cultures (Table 1), are among the most well 
characterized lncRNAs and have been reported to promote cell proliferation through regulation 
of gene expression at the nuclear level. MALAT1 is a mostly un-spliced transcript around 6.7 
kb in mouse, with a long half-life due to the tRNA-OLNHVWUXFWXUHDGRSWHGDWWKH¶HQG [37]. This 
structure is cleaved to generate a 61 nt mascRNA (MALAT1-associated small cytoplasmic 
RNA) exported to the cytoplasm where it is subjected to canonical CCA nucleotides addition 
and accumulates in the cytoplasm [71,72]. We were able to identify the JH002628.1 genomic 
region in Chinese hamster using the abovementioned complementary approaches and we 
could recognize all of its main conserved domains (Supplementary Figure 2). The structure of 
this genomic region is conserved in the most recent CHOK1GS_HDv1 genome and resembles 
the pattern found in human and mouse, where close to MALAT1 is the NEAT1 locus. The 
1($7ORFXVLVUHJXODWHGE\DOWHUQDWLYHƍHQGSURFHVVLQJwhere the primary transcript can 
EHFOHDYHGDQGSRO\DGHQ\ODWHGWRJHQHUDWHDNEORQJ0(1İLVRIRUPRUFOHDYHGDQGQRQ-
SRO\DGHQ\ODWHGWRJHQHUDWHWKHNEORQJ0(1ȕLVRIRUP [37]. We were able to identify a 
predicted 3.2 kb long non-coding transcript (NCBI Ref XR_478750.2) arising from a locus 
(LOC103159497, C_griseus_v1.0) with similar primary structure to both the 3.2 kb and the 
20.8 kb isoforms (E-value 0.0, Identity 80%, algorithm megablast). MALAT1 and NEAT1 both 
localize to the paraspeckles stress-responsive nuclear bodies in the cell [73], where they are 
reported to influence the splicing machinery [70,74] and the DNA repair machinery [75]. The 
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Plasmacytoma Variant Translocation 1 (PVT1) lncRNA is considered a biomarker for various 
cancers due to its ability to promote cell proliferation with a range of proposed mechanisms 
[76±79]. We identified a predicted non-coding RNA in Chinese hamster (NCBI Ref 
XR_478426.2) which contained the PVT1_3 RFAM domain and was up-regulated at both Day 
4 (FDR = 1.2E-01) and Day 7 in the Fed-batch compared to Batch (Table 1).  
3.4 Comparison of mRNAs with Existing Datasets 
We compared our Fed-batch against Batch dataset with previous work to identify coding genes 
related to growth in CHO. Although all these works used different approaches and cell lines, 
we saw the opportunity to find common patterns of expression in CHO across various 
conditions. The first dataset compared was Clarke 2011 [80], where we observed 10 of their 
reported down-regulated genes at Day 4 and 7 at Day 7 of our dataset (Supplementary Table 
13). On comparing our data to Clarke 2012 [81], only the kinesin family member C1 (KIFC1) 
gene, up-regulated at both Day 4 and Day 7, was observed to behave in the same way. Lastly, 
when we considered the translatome analysis in Courtes 2013 we identified 3 genes at Day 4 
and 8 genes at Day 7 among our down-regulated transcripts, together with 1 gene at Day 4 
and 2 genes at Day 7 among the up-regulated transcripts [82]. Interestingly, a group of the 
common genes between the selected works and our dataset (CDC20, MAD2L1, MCM7, 
MCM4, GTF2H4) are involved in cell cycle and DNA replication, supporting the findings in the 
pathway enrichment analysis (described in section 3.5) [83±85] . In addition, we found single 
genes in consistently enriched pathways in our pathway analysis such as HNRNPC, involved 
in RNA molecule binding or LGMN, participating in protein degradation in the lysosome [86]. 
Interestingly, HNRNPs proteins are well known to bind and mediate the functions of lncRNAs, 
and HNRNPC in particular has been reported to interact with MALAT1 in a tightly regulated 
N6-methyladenosine-dependent manner [87,88]. 
3.5 GO analysis and Pathway Enrichment 
We performed GO term analysis on the differentially expressed mRNAs with an FDR cut-off 
of 0.10 calculated by the BH method, followed by pathway enrichment analysis based on the 
KEGG database (Supplementary Tables14-29), allowing the determination of the significantly 
enriched biological pathways filtered for an FDR DQG grouped based on KEGG class 
annotation (Table 2). The pathway enrichment identified 22 pathways containing down-
regulated genes at Fed-batch vs Batch Day 4 and 24 at Fed-batch vs Batch Day 7 while only 
1 contained up-regulated genes (Lysosome, ID: 04142) at either day. This is most likely a 
reflection of the lower number of up-regulated genes compared to down-regulated (Figure 3). 
The Metabolism domain includes 7 enriched pathways at Day 4 while only 1 of these was still 
enriched at Day 7, suggesting a central role of metabolism together with p53 signalling 
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predominantly during the exponential growth phase. On the contrary, towards Day 7 we see 
the prevalent enrichment of pathways related to translation regulation and RNA interaction at 
different levels, from transport to splicing. The most evident pattern of enrichment between 
Day 4 and Day 7 is represented by the Replication and Repair class, where the majority of the 
pathways involved in genome maintenance and diverse repair mechanisms are consistently 
enriched, indicating an early and sustained regulation of these genes throughout culture. DNA 
damage is reported to stimulate the expression of NEAT1 and, together with MALAT1, to 
promote the formation of paraspeckles, which regulate alternative splicing and promote 
proliferation [73,75,89]. We then compared our results with relevant KEGG pathway 
enrichment datasets available for CHO [90] and found 4 common pathways, which were 
enriched exclusively at Day 7 in our dataset: RNA Transport (ID: 03013), mRNA surveillance 
(ID: 03015), RNA degradation (ID: 03018), Spliceosome (ID: 03040). Taken together, these 
results suggest the importance of cell cycle and genome repair mechanism control likely due 
to the high proliferation of the fed-batch system. In addition, the active regulation of RNA 
transport, RNA maintenance and splicing seems to be particularly important towards the later 
stages of our Fed-batch cultures. 
4. DISCUSSION 
By taking advantage of a comprehensive commercially available mouse microarray containing 
35923 lncRNAs and 24881 mRNAs, we have provided the first mapping of the CHO lncRNA 
landscape, together with the coding transcriptome. Previous reports have shown that more 
than 70% of the assembled CHO transcriptome is similar to mouse (Mus musculus) and 
closely related to rat (Rattus norvegicus) transcriptomes [58] suggesting that this approach 
was likely to be valid for lncRNAs as well. Due to the species and tissue-specificity of lncRNAs 
compared to mRNAs, the number of detectable lncRNAs in CHO is likely to be lower than the 
35923 probes included in the array. Nevertheless, using this approach we were able to detect 
24603 lncRNAs (68.5% of the total probes) and 19617 mRNAs (78.8% of the total probes), 
and found that t several hundreds of lncRNAs exhibit changing expression profiles on different 
days of culture and between Batch and Fed-batch culture in a model CHO-S system. This was 
especially true for the Fed system, where comparing Day 4 and Day 7 we observed 1114 
differentially expressed mRNAs and 745 lncRNAs, as opposed to the Batch, were we saw 
only 19 differentially expressed mRNAs and no lncRNA for the same comparison, suggesting 
a prevalent variability induced by the Fed supplement as compared to time only.  
Among the differentially expressed genes, between 16-28% of the lncRNAs probes had a 
matching transcript in CH, as opposed to 58-80% of the mRNAs. This required a specific 
approach where the Chinese hamster genome, literature search and databases mining were 
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combined to detect lncRNAs differentially expressed in our system with an established 
biological function. Within these lncRNAs, we focused on MALAT1, NEAT1 and PVT1 to 
provide a comparison between the mouse gene and the Chinese hamster putative 
homologues. The number of lncRNAs with a fully understood role in the cell remains small, 
however these three non-coding genes are among the most well characterized [91]. MALAT1 
and NEAT1 in particular are associated with increased proliferation and participate in the 
regulation of alternative splicing and DNA repair, which we found to be strongly regulated in 
our pathway enrichment analysis. This suggests a potential role for these lncRNAs in CHO, 
although further experimental studies on the single genes are now required to assess the 
actual effects on the cell under different conditions.  
Several approaches to investigate and confirm the functional annotation of lncRNAs in other 
organisms have been described, including the perturbation of lncRNA expression by 
overexpression, knockout or knockdown [92,93], in addition to complementary strategies [39]. 
Future developments in CHO will have to proceed with a mix of functional prediction tools to 
assess the properties of the transcriptome and evaluate the degree of conservation with other 
species [94±96] and of targeted approaches to ameliorate the annotation and propose 
mechanisms of action for the single transcripts [97±100]. Further, the data reported here is for 
both lncRNAs and mRNAs and hence will allow investigators to further probe the relationships 
between the expression and regulation of these two classes of RNA. As the majority of the 
lncRNAs reported in the literature are discussed and related to human or model organism 
systems, our work aimed at unveiling the role of lncRNAs in CHO under industrially relevant 
conditions to identify new targets for manipulation to sustain proliferation. Examples of 
successful cell engineering of lncRNAs to selectively enhance translation [101] and product 
yield [57] have already been reported in CHO, demonstrating the potential of manipulation of 
lncRNAs for enhancing industrial processes. Moreover, since it was reported up to 15% of the 
total ribosome occupancy can be occupied by a single recombinant mRNA, the intrinsic 
characteristics of lncRNAs place them as ideal candidates for cell line engineering of protein 
production cell factories, as they do not add any translational burden on top of the coding gene 
of interest [102].  
Our work has identified potential lncRNA targets differentially expressed in Fed-batch 
compared to Batch culture from which we selected a group of molecules to be experimentally 
studied (Table 1). In addition to the expression of lncRNAs we also looked at expression of 
mRNAs (coding transcripts) and found a consistent change in differentially expressed mRNAs 
when comparing batch and fed-batch cultures. Pathway enrichment analysis (Figure 3) 
underlined the importance of genes involved in cell cycle and genome maintenance pathways 
along with the regulation of lysosome formation as potential targets for cell engineering to 
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enhance proliferation. Our approach allowed the identification of previously undescribed 
lncRNAs in CHO along with mRNAs to identify the connections between them and compared 
these with existent literature. This network of reciprocal interactions is beginning to be unveiled 
in other organisms [103±105] and our work will help pave the way for the definition of new 
layers of regulation involving single transcripts or even entire pathways in CHO. 
5. CONCLUSIONS 
He we report on the lncRNA landscape and how this changes in CHO cells, presenting a full 
dataset of those lncRNAs present as determined from an array study and how these change 
through a Batch and Fed-batch culture and between the two culture systems. From analysis 
of the data, we have determined those lncRNAs whose expression changes the most between 
2 days in culture and between fed and batch culture that are attractive targets for cell 
engineering. This resource will now provide the community with the opportunity to undertake 
functional validation studies by undertaking single or multiple knock downs/outs, or by the up-
regulation of target lncRNAs, and determine the impact on growth, and productivity, 
characteristics of CHO cells. Ultimately, we anticipate such a resource will be incorporated 
into wider genome analysis datasets including coding mRNAs and other non-coding RNAs to 
develop a wider appreciation of the role of RNAs in controlling recombinant CHO cell line 
growth and productivity characteristics. 
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Table 1: Summary of the lncRNAs identified using the described approaches, consisting in a direct alignment of the differentially 
expressed gene probe against the Chinese hamster genome to literature search and RNA families conservation in RFAM. From left to 
right, the columns show the gene symbol, the NCBI accession reference, the fold-change measured at Day 4 and Day 7 with the 
corresponding FDRs, the ID of the non-coding RNA family found for the sequence in Rfam database with the corresponding ID and E-















Rfam ID E-value References 
MALAT1 JH002628.1 3.5 4.5 2.4E-02 1.0E-02 MALAT1 RF01871 7.5E-13 Sun 2017, Wilusz 2016 





MEG3 JH001208.1 2.9 2.8 5.9E-02 4.7E-02 MEG3_2 RF01872 3.5E-14 He 2017 
MIAT XM_007625231.2 2.6 0.0 2.6E+00 1.0E-02 MIAT_exon1 RF01874 7.0E-12 Liao 2016 
NEAT1 XR_478750.2 6.1 3.3 3.9E-02 6.3E-02 NEAT1_1 RF01955 5.4E-18 Adriaens 2016, Hirose 2014  
      
NEAT1_2 RF01956 1.2E-17 
 
      
NEAT1_3 RF01957 2.2E-19 
 
PVT1 XR_478426.2 2.5 3.5 1.2E-01 2.7E-02 PVT1_3 RF02166 1.7E-16 Colombo 2015, Zhu 2017 
TERC AF221928.1 - 6.3 - 4.0E-02 Telomerase-vert RF00024 5.7E-58 Engreitz 2016 
TUG1 XR_483407.1 - 2.1 - 8.0E-02 TUG1_3 RF01891 1.6E-46 Li 2016 
      
TUG1_1 RF01882 1.3E-21 
 
      
TUG1_4 RF01892 2.1E-20 
 
      





Table 2: Summary of the enriched pathways based on the list of up-regulated (lysosome) and down-regulated (lower tables) transcripts 
in Fed-batch vs Batch comparison at Day 4 (left panel) and Day 7 (right panel). The columns show from left to right the ID from KEGG, 
the pathway name, the FDR associated with the enrLFKPHQW)'5WKUHVKROG, the number of differentially expressed genes in 
the pathway, the number of total genes listed in the pathway, the differentially expressed genes over total genes ratio.  
 
UP fed D4 v batch D4 
KEGG ID Pathway FDR Diff. Expressed  (DE) genes 




04142 Lysosome 6.3E-02 14 124 0.11 
 
UP fed D7 v batch D7 
KEGG ID Pathway FDR Diff. Expressed  (DE) genes 




04142 Lysosome 7.1E-04 21 124 0.17 
 
DOWN fed D4 v batch D4 
KEGG ID Pathway FDR Diff. Expressed  (DE) genes 




05034 Alcoholism 8.5E-11 48 203 0.24 
04110 Cell cycle 2.3E-09 34 125 0.27 
05322 Systemic lupus erythematosus 6.8E-07 33 147 0.22 
03030 DNA replication 3.5E-04 12 35 0.34 
03460 Fanconi anemia pathway 8.5E-04 14 51 0.27 
05203 Viral carcinogenesis 1.1E-03 37 243 0.15 
03410 Base excision repair 1.3E-03 11 35 0.31 
03430 Mismatch repair 4.4E-03 8 22 0.36 
01200 Carbon metabolism 4.5E-03 21 117 0.18 
 21 
00480 Glutathione metabolism 5.7E-03 13 56 0.23 
00900 Terpenoid backbone biosynthesis 6.4E-03 8 24 0.33 
04114 Oocyte meiosis 8.5E-03 20 116 0.17 
05200 Pathways in cancer 1.3E-02 48 397 0.12 
03440 Homologous recombination 1.6E-02 8 28 0.29 
04914 Progesterone-mediated oocyte maturation 1.8E-02 16 90 0.18 
01212 Fatty acid metabolism 2.1E-02 11 51 0.22 
04540 Gap junction 2.8E-02 15 86 0.17 
00280 Valine, leucine and isoleucine degradation 4.2E-02 11 56 0.20 
04115 p53 signaling pathway 6.4E-02 12 68 0.18 
00240 Pyrimidine metabolism 6.4E-02 16 104 0.15 
03420 Nucleotide excision repair 6.5E-02 9 44 0.20 
00630 Glyoxylate and dicarboxylate metabolism 7.6E-02 7 30 0.23 
 
 
DOWN fed D7 v batch D7 
KEGG ID Pathway FDR Diff. Expressed  (DE) genes 




04110 Cell cycle 7.9E-14 38 125 0.30 
03030 DNA replication 1.2E-09 17 35 0.49 
03013 RNA transport 1.2E-09 38 170 0.22 
03040 Spliceosome 1.3E-07 30 134 0.22 
05203 Viral carcinogenesis 2.8E-06 40 243 0.16 
03430 Mismatch repair 2.2E-05 10 22 0.45 
03460 Fanconi anemia pathway 2.3E-05 15 51 0.29 
03410 Base excision repair 3.3E-04 11 35 0.31 
 22 
05322 Systemic lupus erythematosus 9.3E-04 24 147 0.16 
03440 Homologous recombination 1.4E-03 9 28 0.32 
03420 Nucleotide excision repair 2.5E-03 11 44 0.25 
05034 Alcoholism 3.5E-03 28 203 0.14 
04114 Oocyte meiosis 4.2E-03 19 116 0.16 
03008 Ribosome biogenesis in eukaryotes 2.0E-02 14 83 0.17 
00240 Pyrimidine metabolism 2.3E-02 16 104 0.15 
03015 mRNA surveillance pathway 2.6E-02 15 96 0.16 
00310 Lysine degradation 3.1E-02 10 52 0.19 
04914 Progesterone-mediated oocyte maturation 3.4E-02 14 90 0.16 
03018 RNA degradation 4.4E-02 13 83 0.16 
05166 HTLV-I infection 4.8E-02 32 294 0.11 
05222 Small cell lung cancer 4.9E-02 13 85 0.15 
00020 Citrate cycle (TCA cycle) 5.5E-02 7 32 0.22 
05215 Prostate cancer 6.7E-02 13 89 0.15 
01210 2-Oxocarboxylic acid metabolism 1.0E-01 5 20 0.25 


























Figure 1: Summary of the experimental workflow. Growth and culture viability of a CHO-S cell line 
in Batch and Fed-batch cultures were measured for 10 days and samples for RNA extraction taken 
at Day 4 and at Day 7. The samples were analysed on a mouse array containing all the coding and 
non-coding transcripts stored in the main public databases. The measured intensities were log-
QRUPDOL]HGDQGGLIIHUHQWLDOO\H[SUHVVHGWUDQVFULSWVJHQHVZHUHILOWHUHGIRUDIROGFKDQJH)&
DQGDQ)'5$VHOHFWHGJURXSRIgenes was validated through RT-qPCR (Supplementary 
Material). Due to the poor annotation of lncRNAs in CHO, the identification of potential targets with 
a described biological role required the comparison of human and mouse literature and databases, 
followed by alignment against the Chinese hamster genome, leading to predicted lncRNAs 
transcripts and previously un-annotated genomic regions (Table 1). At the same time, GO and 































Figure 2. A) Growth profiles for the model CHO-S host cell line throughout Batch and Fed-batch 
culture. Viable cell concentration (VCC) and culture viability are shown (red for Batch and blue 
for Fed-batch). The percentage of CHO CD Efficient Feed B Liquid Nutrient Supplement added 
to the existing working volume are shown for each feeding day (days 0, 3 and 6). The arrows 
indicate when samples for microarray analysis were harvested (Day 4 and Day 7). B) Hierarchical 
clustering heatmaps arranging samples into groups based on their averaged log-normalized 
expression levels. Only transcripts/genes with an expression variance between each group above 
the 80th percentile are shown. The dendrogram shows the relationships for lncRNAs (left panel) 
and mRNAs (right panel). C) Down-regulated (green bars) and up-regulated (red bars) mRNAs 
(full bars) and lncRNAs (textured bars) in CHO-S cells during batch and fed-batch culture for 
HDFKRIWKHFRPSDUHGSDLUVVKRZLQJDIROGFKDQJHDQGDQ)'5'9HQQGLDJUDPV
showing the number of lncRNAs and mRNAs differentially expressed (DE) in Fed-batch vs Batch 
)&)'5*HQHV'(DWERWK'D\DQG'D\DUHUepresented in the overlaps while 






Figure 3: Graphical representation of the enriched KEGG pathways listed in Table 2, 
hierarchically grouped based on KEGG Pathway Maps. Each filled rectangle (in red for Day 4, in 
blue for Day 7) contains the corresponding enriched pathways, with pathways enriched at both 
Day 4 and Day 7 enclosed in the overlaps between the filled rectangles. The enrichment is based 
on genes differentially expressed in Fed-EDWFKYV%DWFKDW'D\DQG'D\ZLWKDQ)'5 
